Heart failure is a heterogeneous condition in which the heart cannot pump out enough blood to meet the body's metabolic needs . It can be caused by structural defects, functional abnormalities (ventricular dysfunction), or sudden overload . Hospitalization is defined as the confinement of a patient in a hospital .

In patients with HFrEF and NYHA class II to III symptoms, the use of an angiotensin receptor-neprilysin inhibitor (ARNi) is recommended to reduce morbidity and mortality . In patients with HFrEF with current or previous symptoms, one of three beta blockers proven to reduce mortality (bisoprolol, carvedilol, sustained-release metoprolol succinate) is recommended to reduce mortality and hospitalizations . In patients with HFrEF and NYHA class II to IV symptoms, a mineralocorticoid receptor antagonist (MRA) such as spironolactone or eplerenone is recommended if eGFR is >30 mL/min/1.73 m2 and serum potassium is <5.0 mEq/L . Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are also recommended to reduce hospitalization for heart failure and cardiovascular mortality in patients with symptomatic chronic HFrEF, regardless of type 2 diabetes presence .

Heart Failure

Heart failure hospitalization

Q: Diagnosis and risk stratification

Risk stratification is critical for managing acute heart failure in older adults . The EHMRG-BI model, integrating brain natriuretic peptide and endotracheal intubation with the Emergency Heart Failure Mortality Risk Grade score, has been proposed to improve 30-day mortality prediction in geriatric heart failure, though its clinical applicability requires further refinement and external validation . Furthermore, a large-scale analysis of 16,128 hypertensive UK Biobank participants investigated a plasma protein risk score using 2,911 proteins to enhance the prediction of heart failure among hypertensive individuals before overt disease occurs .

Q: Guideline recommendations

Current guideline recommendations: Class I, Level A: In patients with HFrEF and NYHA class II to III symptoms, the use of ARNi is recommended to reduce morbidity and mortality. | Class I, Level A: In patients with HFrEF, with current or previous symptoms, use of 1 of the 3 beta blockers proven to reduce mortality (e.g., bisoprolol, carvedilol, sustained-release metoprolol succinate) is recommended to reduce mortality and hospitalizations. | Class I, Level A: In patients with HFrEF and NYHA class II to IV symptoms, an MRA (spironolactone or eplerenone) is recommended to reduce morbidity and mortality, if eGFR is >30 mL/min/1.73 m2 and serum potassium is <5.0 mEq/L. | Class I, Level A: In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce hospitalization for HF and cardiovascular mortality, irrespective of the presence of type 2 diabetes.

Acute decompensated HF and hospitalization outcomes

Also called ADHF, acute heart failure, HF admission

Sources: 4 guideline recommendations · 12 new papers · 5 key papers · updated Oct 20, 2026

Overview

Unverified · drafted by AI from the sources cited below

Definition

Heart failure is a heterogeneous condition in which the heart cannot pump out enough blood to meet the body's metabolic needs.1

Diagnosis and risk stratification

Risk stratification is critical for managing acute heart failure in older adults.1 The EHMRG-BI model, integrating brain natriuretic peptide and endotracheal intubation with the Emergency Heart Failure Mortality Risk Grade score, has been proposed to improve 30-day mortality prediction in geriatric heart failure, though its clinical applicability requires further refinement and external validation.1 Furthermore, a large-scale analysis of 16,128 hypertensive UK Biobank participants investigated a plasma protein risk score using 2,911 proteins to enhance the prediction of heart failure among hypertensive individuals before overt disease occurs.2

Treatment

In patients with HFrEF and NYHA class II to III symptoms, the use of an angiotensin receptor-neprilysin inhibitor (ARNi) is recommended to reduce morbidity and mortality.1 In patients with HFrEF with current or previous symptoms, one of three beta blockers proven to reduce mortality (bisoprolol, carvedilol, sustained-release metoprolol succinate) is recommended to reduce mortality and hospitalizations.2 In patients with HFrEF and NYHA class II to IV symptoms, a mineralocorticoid receptor antagonist (MRA) such as spironolactone or eplerenone is recommended if eGFR is >30 mL/min/1.73 m2 and serum potassium is <5.0 mEq/L.3 Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are also recommended to reduce hospitalization for heart failure and cardiovascular mortality in patients with symptomatic chronic HFrEF, regardless of type 2 diabetes presence.4

Guideline recommendations

Class of recommendation is how strongly the society advises the action (I is strongest, III is not recommended). Level of evidence is the kind of studies behind it (A is randomized trials, C is expert opinion or limited data).

4 recommendations on heart failure hospitalization from 1 guideline, by strength.

ACC/AHA/HFSA 20224

Class IClass IIaClass IIbClass III

The strongest 4 recommendations

ACC/AHA/HFSA 2022 · Source

Class ILevel A

In patients with HFrEF and NYHA class II to III symptoms, the use of ARNi is recommended to reduce morbidity and mortality.

For: Adults with HFrEF and NYHA class II to III symptomssacubitril/valsartanARNI

Class ILevel A

In patients with HFrEF, with current or previous symptoms, use of 1 of the 3 beta blockers proven to reduce mortality (e.g., bisoprolol, carvedilol, sustained-release metoprolol succinate) is recommended to reduce mortality and hospitalizations.

For: Adults with HFrEF and current or previous symptomsbisoprololcarvedilolmetoprolol succinatebeta blockers

Class ILevel A

In patients with HFrEF and NYHA class II to IV symptoms, an MRA (spironolactone or eplerenone) is recommended to reduce morbidity and mortality, if eGFR is >30 mL/min/1.73 m2 and serum potassium is <5.0 mEq/L.

For: Adults with HFrEF and NYHA class II to IV symptoms, eGFR >30, and serum potassium <5.0 mEq/Lspironolactoneeplerenonemineralocorticoid receptor antagonists

Class ILevel A

In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce hospitalization for HF and cardiovascular mortality, irrespective of the presence of type 2 diabetes.

For: Adults with symptomatic chronic HFrEF, irrespective of type 2 diabetesdapagliflozinempagliflozinSGLT2 inhibitors

How this page is built

A clinical question appears here only when its condition matches this topic, an outcome and a comparator were extracted from the studies, at least two studies and a patient count are on file, and the certainty is low or higher.

Supports benefit, no benefit shown, and mixed describe the direction of the measured effect. No benefit shown means the evidence does not support a benefit. It is not a finding of harm. Too little evidence means the question did not clear that bar.

Study count, RCT count, and patient count are separate. The patient total adds only studies that are linked into a study family and whose sample size is not flagged as implausible. A reversal is listed only when at least one randomized trial sits on each side of the change.

The overview is drafted from the guideline recommendations, trials, papers, and questions on this page, and every sentence has to cite one of them. It stays unverified until an NPI-verified clinician or a Synapse admin approves it. Approving records that person's name.

Heart failure hospitalization

Overview

Definition

Diagnosis and risk stratification

Treatment

New research on Heart failure hospitalization

Guideline recommendations

ACC/AHA/HFSA 2022 · Source

Journal clubs discussing Heart failure hospitalization

Recent sessions

Journal Club takes on Heart failure hospitalization

Key papers

How this page is built

Journal Club takes on Heart failure hospitalization

Leading authors